T. Rowe Price Associates’s Amylyx Pharmaceuticals AMLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $586K | Buy |
91,392
+33,692
| +58% | +$216K | ﹤0.01% | 2230 |
|
|
2025
Q1 | $205K | Hold |
57,700
| – | – | ﹤0.01% | 2616 |
|
|
2024
Q4 | $219K | Buy |
57,700
+2,100
| +4% | +$7.97K | ﹤0.01% | 2631 |
|
|
2024
Q3 | $181K | Hold |
55,600
| – | – | ﹤0.01% | 2685 |
|
|
2024
Q2 | $106K | Sell |
55,600
-914,955
| -94% | -$1.74M | ﹤0.01% | 2752 |
|
|
2024
Q1 | $2.76M | Buy |
970,555
+75,775
| +8% | +$215K | ﹤0.01% | 1427 |
|
|
2023
Q4 | $13.2M | Buy |
894,780
+870,560
| +3,594% | +$12.8M | ﹤0.01% | 1040 |
|
|
2023
Q3 | $444K | Buy |
24,220
+1,132
| +5% | +$20.8K | ﹤0.01% | 2159 |
|
|
2023
Q2 | $499K | Buy |
23,088
+581
| +3% | +$12.6K | ﹤0.01% | 2131 |
|
|
2023
Q1 | $661K | Buy |
22,507
+6,824
| +44% | +$200K | ﹤0.01% | 1988 |
|
|
2022
Q4 | $579K | Buy |
+15,683
| New | +$579K | ﹤0.01% | 2069 |
|